Donor lymphocyte infusions (DLI) following allogeneic stem cell transplantation are known to mediate graft-versusleukemia effect (GVL). A major side effect of these immunotherapies is the development of graft-versus-host diseases (GVHD). One promising approach to prevent GVHD is to genetically modify donor T cells with a suicide mechanism that can be induced in the case of GVHD. Here we report on a retroviral vector containing the death effector domain (DED) of the human Fas-associated protein with death domain (FADD). The DED was fused to two copies of an FKBP506-binding protein and a truncated version of the human low-affinity receptor for nerve growth factor (LNGFR). Activation of the death signal pathway can be triggered upon the addition of chemical inducers of dimerization. This construct was functionally compared to an optimized HSV-TK vector in which a hypersensitive mutant of the herpes simplex virus thymidine kinase gene (TK39) was fused to a cytoplasmic truncated version of the cell surface antigen CD34. A direct comparison between both vectors in primary T lymphocytes showed that the number of T cells transduced with vectors containing the DED was significantly reduced within 24 h of drug administration whereas ganciclovir treatment of TK39-transduced T cells showed a delay in cell death of approximately 3-4 days. Our results indicate that constructs containing the DED may prove to be the most efficient mechanism to quickly eliminate alloreactive T cells.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a curative approach for the treatment of hematological disorders is often complicated by severe graft-versus-host disease (GVHD) mediated by T cells in the graft. 1, 2 Depletion of these cells has proven to be an effective method for preventing acute GVHD in allo-HSCT. 3 Unfortunately, this procedure is associated with an increased incidence of graft rejection and leukemic relapse as well as life-threatening viral and fungal infections. 4 These and other findings suggest that donor lymphocyte infusions (DLI) might be efficient in both controlling disease relapse 5 and in accelerating immune reconstitution. 6, 7 Thus, major efforts are currently focused on the development of strategies for the beneficial use of DLI in the control of disease relapse while preventing its adverse effects, namely GVHD.
Previously, it was shown that the ex vivo introduction of a suicide gene provides a means for the specific elimination of the donor T cells within the onset of GVHD. [6] [7] [8] In most cases, donor T cells have been equipped with the herpes simplex virus thymidine kinase (HSV-TK) gene. Upon incubation with ganciclovir (GCV), this kinase phosphorylates nucleoside analogs converting them to monophosphorylated forms. These in turn are anabolized by cellular kinases to the corresponding nucleoside triphosphates. Incorporation of these nucleoside derivates into newly synthesized DNA results in the arrest of DNA synthesis followed by DNA fragmentation and cell death. [7] [8] [9] [10] [11] [12] In the first clinical study using HSV-TK-modified T cells for the control of GVHD, all patients who developed GVHD responded to GCV. 6 However, in one patient only partial response was achieved and transduced T cells were still detected after GCV treatment. The development of a partial GCV resistance was explained by cryptic splice donor and acceptor sites within the HSV-TK sequence 13 as well as the cell-cycle dependence of the HSV-TK/GCV system, pointing out to some of the limitations of this approach. Furthermore, a cytotoxic Tcell-mediated immune response against the HSV-TK gene product was detected in several patients treated with HSV-TK-transduced T lymphocytes resulting in the elimination of the genetically modified T cells. 14 In addition, high doses of GCV have been shown to be myelosuppressive. To overcome toxicity, HSV-TK mutants with increased affinity for GCV and acyclovir (ACV) have been described. 15, 16 Recently, an alternative to the HSV-TK/GCV suicide system based on the use of the Fas receptor to trigger cell death was reported. In this system, the intracellular domain of the Fas receptor was fused to two modified copies of FKBP12, which in turn were ligated to a truncated version of the human low-affinity receptor for nerve growth factor. 14 Crosslinking of the Fas receptor through binding of a bivalent synthetic molecule to FKBP12 resulted in the recruitment of a death-inducing signaling complex (DISC) leading to the activation of caspases and, ultimately, to cell death. 17 Here, we describe the development of a novel suicide vector based on the expression of the death effector domain (DED) of the Fas-associated protein with death domain (FADD). We present evidence that T cell lines and primary T lymphocytes are extremely sensitive to DED-induced cell death. Dimerization and activation of DED was achieved by a molecular switch similar to that described previously by Thomis et al.
14 Moreover, we compared this construct to an optimized TK vector in which a hypersensitive mutant of TK, SRTK39, 15 was fused in frame to a naturally occurring splice variant of the human CD34 antigen. 18 Both constructs were tested in parallel for efficacy and kinetics of cell death induction in T cell lines and primary T lymphocytes.
Our results show that T cells expressing the DED are eliminated much faster than those expressing the TK39 gene. This suggests that constructs triggering cell death through components of the Fas signaling pathway should be preferred for the genetic modification of T cells in forthcoming applications of DLI.
Results

Construction of suicide vectors containing chimeric fusion proteins
The genetic modification of T lymphocytes in the context of DLI for the treatment of malignancies requires the coexpression of a suicide gene and a selectable marker gene. Although several strategies have been described for the coexpression of two genes from a common retroviral vector backbone, the most efficient strategy so far would be to fuse both coding regions to generate a chimeric protein. Therefore, we decided to construct two chimeric proteins for use in DLI-based therapy and compared their ability to trigger induced cell death in transduced T cell lines and primary T lymphocytes.
In the first construct, a truncated version of the lowaffinity receptor for nerve growth factor (tLNGFR, 19) was fused to two divergent copies of an FKBP point mutant called F36V-FKBP, which binds with high affinity and specificity to the dimerizer drug AP20187. 20 Both copies, F36V-FKBP and F36V 0 -FKBP, encode for identical polypeptides but differ in their nucleotide sequence by 38%. The rationale behind this strategy was to reduce the risk of recombination between two identical tandem copies of F36V-FKBP during retroviral replication cycle. 14 The tLNGFR/F36V 0 F36V fusion construct was further linked via a glycine-serine spacer (SGSGGGS) to a DNA fragment coding for 100 amino acids derived from the N-terminus of human FADD, which contains the DED of FADD. Upon addition of the chemical inducer of dimerization AP20187, the fusion protein tLNGFR/ F36V 0 F36V/DED crosslinks and triggers apoptosis in transduced cells.
In a second construct, a splice-corrected version of a hypersensitive mutant of HSV-TK was fused to a naturally occurring splice variant of the human CD34 antigen (tCD34,18). This TK mutant (SR39 in Black et al 15 ) was isolated from a semirandom mutagenesis screen of the active site of HSV-TK with the purpose of selecting TK mutants with higher affinity for the cytotoxic drugs GCV and ACV. The TK39 mutant contains five divergent amino acids from wild-type TK and confers 294-and 182-fold enhanced sensitivity to growth inhibition by GCV and ACV, respectively. The tCD34 molecule contains the extracellular domain, the transmembrane domain and only 16 amino acids of the cytoplasmic domain of wildtype CD34 and therefore lacks the recognition sites for phosphokinase C. We chose this molecule as a selection marker because it is not expressed on the surface of mature T cells and allows purification of CD34-expressing cells according to GMP guidelines. The splicecorrected TK39 gene was fused in frame to tCD34.
These fusion constructs were cloned in the same retroviral vector backbone to allow a direct comparison of both systems in transduced T cell lines and primary T lymphocytes. The retroviral vector contains the LTR of the myeloproliferative sarcoma virus (MPSV), since this LTR allows high levels of transgene expression in T cell lines and primary T lymphocytes. 21 Furthermore, we included the WPRE that is known to further enhance transgene expression levels. 22 The resulting vectors were designated MNV 0 VDEDw and MtCD34TK39mw ( Figure 1 ).
Functional characterization of MtCD34TK39mw and MNV
0 VDEDw
The MtCD34TK39mw and MNV 0 VDEDw constructs were tested for functionality in HUT 78 cells. Retroviral Kinetics of cell death triggered by suicide genes K Junker et al vectors pseudotyped with GALV envelope 23 were produced by transient transfection and used to transduce HUT 78 cells. CD34-or LNGFR-expressing cells were separated to more than 95% purity by MACS (data not shown). Both fusion proteins were expressed in the transduced cells as estimated by Western blotting. In MtCD34TK39mw-transduced cells, a band of approximately 160 kDa was detected with an anti-CD34 antibody (sc-9095, Santa Cruz Biotechnology, CA, USA), whereas a specific band of approximately 70 kDa MW was detected by an LNGFR mAb (C40-1457, BDPharmingen, Heidelberg, Germany) in cell lysates obtained from MNV 0 VDEDw-transduced cells (data not shown). We next assessed the susceptibility of transduced and selected HUT 78 cells to GCV or AP20187-induced cell death. Transduced cells were exposed to increasing concentrations of GCV or AP20187 for 4 or 3 days, respectively. Maximal induced cell death occurred in the presence of 1-100 mM GCV in MtCD34TK39mw-transduced HUT 78 cells ( Figure 2a ). The IC 50 was approximately 0.08 mM. The maximal killing efficiency was consistently within the range of 90 and 95%. GCV treatment of mock-transduced or untransduced control cells showed no significant effect on cell survival below 100 mM GCV (Figure 2a ). In MNV 0 VDEDw-transduced HUT 78 cells, significant cell death was observed at concentrations as low as 0.1 nM AP20187 and a maximum effect was achieved at concentrations between 1 and 10 nM ( Figure 2B ). The IC 50 was approximately 0.05 nM. The killing efficiency ranged between 85 and 90%. Treatment of nontransduced cells with AP20187 did not cause a significant decrease in cell numbers.
Long-term expression of both constructs was tested in HUT 78 cells for a total of 12 weeks. Cell surface marker expression was retained during this time and cell killing by GCV or AP20187 was indistinguishable from that observed 1 week after transduction (data not shown).
Induction of apoptosis in transduced primary T cells
Primary CD3-enriched human T lymphocytes were prestimulated for 3 days and transduced for a total of 4 h at an MOI of 1.5 on 3 consecutive days. Transduction efficiencies ranged between 35 and 50% for both constructs (Figure 3b ). Cytotoxicity assays were performed with unsorted cell populations by analysis of cell surface marker expression among living cells. Alternatively, transduced cells were purified by immunomagnetic beads based on their cell surface marker expression. Generally, purities above 91% were achieved after a single round of selection ( Figure 3c ). Importantly, there was no cytotoxicity associated with the crosslinking of the LNGFR fusion protein by LNGFR antibody binding, indicating that antibody binding is not sufficient to trigger receptor dimerization and death induction through the DED. An estimation of the copy number by semiquantitative PCR indicated that T cells transduced with either construct contained one to two copies of the transgenes in their genome (data not shown).
Four days after transduction, primary T lymphocytes were exposed for 4 further days to increasing concentrations of GCV as described for HUT 78 cells. Maximal killing occurred in the range between 1 and 10 mM GCV as determined by FACS analysis of CD34-expressing cells (Figure 4a ) or AnnexinV-FITC staining (data not shown). The maximal killing efficiency ranged between 94 and 97%, whereas mock-transduced control cells were not affected by GCV concentrations lower than 100 mM. The IC 50 was approximately 0.05 mM GCV. The CD34/TK39 fusion protein was as effective as TK39 alone in inducing GCV-dependent cell killing (data not shown).
Similarly, we assessed the AP20187-dependent susceptibility of MNV 0 VDEDw-transduced primary T cells in parallel. The transduced cells were cultured with increasing concentrations of AP20187 for 3 days. Maximal induced cell death occurred at a concentration of 1-10 nM (Figure 4b ) with an efficiency of up to 95%. The estimated IC 50 value was 0.07 nM. Kinetics of cell death triggered by suicide genes K Junker et al only slightly reduced (30%) within the first 24 h of GCV treatment ( Figure 5 ). Only after 72 h culture with GCV, a significant reduction in the number of viable cells was observed (up to 77%). The percentage of cell death increased to 97% upon further treatment with GCV whereas in the population of AP20187-treated cells no further reduction in the number of viable cells was observed. These findings demonstrate that the AP20187-mediated apoptosis in MNV 0 VDEDw-transduced cells allows rapid induction of a significant cell death soon after drug addition.
Effect of in vitro culture or transduction procedure on alloreactivity of T lymphocytes
To determine whether the ex vivo cultured and transduced T lymphocytes retained the ability to generate a specific alloreactive response, flow cytometry-based cytotoxicity assays with leukemic blasts as target cells were performed. Transduced T lymphocytes were purified to almost 100% purity by MACS and cocultured with leukemic blast cells at increasing effector:target (E:T) ratios. Alloreactivity of transduced cells was determined by flow cytometry from the reduction in the number of target cells expressing cell-specific antigens.
No difference in alloreactivity towards leukemic blasts was observed between transduced and untransduced T lymphocytes. Transduced cells show highest cytotoxic activity at E:T ratios between 5:1 and 10:1 and thus are similar to the ratios observed for untransduced cells ( Figure 6 ). These findings indicate that ex vivo cultured and transduced cells retained their alloreactivity against antigens present in leukemic cells and are therefore adequate effector cells against residual leukemic blasts.
Effect of different antiviral drugs on HSV-TK39-expressing cells
GCV is an antiviral drug used in immune suppressed patients for the eradication of herpes simplex and cytomegalovirus (CMV) infections. Its antiviral action is restricted to infected cells, since only virally encoded kinases are able to phosphorylate GCV to its monophosphate derivate. In case of an adoptive immunotherapy with TK-modified T cells, treatment of viral infections with GCV would result in the unwanted elimination of transduced cells and loss of GVL effect.
To provide alternatives to GCV, we analyzed the effects of Cidofovir and ACV on TK39-transduced cells. Cidofovir was developed for the treatment of CMV retinitis, as well as herpes simplex blisters and sores that do not respond to standard ACV. Cidofovir is known to remain inside the cells longer than other drugs and therefore requires less frequent administration. ACV is used to treat symptoms of chickenpox, shingles, herpes virus infections of the genitals, the skin, the brain and the mucous membranes (lips and mouth), as well as for widespread herpes virus infections in newborns.
We performed cytotoxicity assays on TK39-transduced HUT 78 cells as described above. MtCD34TK39 selected cells and nontransduced controls were exposed to increasing concentrations of GCV, ACV and Cidofovir, ranging between 1 mM and 1 mM for 4 days. Cell survival was determined by MTS assays or Annexin staining ( Figure 7) . After GCV treatment, up to 90% of the cells were eliminated at a concentration of 10 mM. Similar results were obtained after treatment with ACV. In contrast, a significant reduction in the number of TK39-expressing cells was observed only at 1 mM Cidofovir (Figure 7a ). This effect was however not specific for TK39-expressing cells, since at this high drug concentra- Kinetics of cell death triggered by suicide genes K Junker et al tion the toxic effects were also observed in the untransduced controls (Figure 7b ). According to these results, Cidofovir could be used as an alternative to GCV for the treatment of viral infection in patients receiving infusions with TK39-transduced lymphocytes. Kinetics of cell death triggered by suicide genes K Junker et al
Discussion
In this report, we compared two suicide mechanisms for the elimination of transduced primary T cells aiming at the use of the genetically modified cells (GMCs) in the context of DLI following allo-HSCT. Focused on improved clinical protocols, both the recently described herpes simplex thymidine kinase gene with enhanced sensitivity to GCV 15 and new approaches for cell killing based on components of the CD95 signaling pathway 14 seemed to be attractive for comparative investigations as an alternative to wild-type TK. However, no side-by-side comparison between both systems has been presented until now. For both systems we used constructs expressing fusion proteins of a suicide gene and a selectable marker gene since this combination represents the optimal configuration for the expression of two genes simultaneously from one vector. In the first construct (MtCD34TK39mw), we fused a truncated version of the CD34 antigen (tCD34) to a mutant form of TK (TKSR39). Using tCD34 as a selection marker allows for the purification of positive cells under clinically relevant conditions. Moreover, the existence of naturally occurring truncated forms of CD34 may preclude immunogenic reactions against the protein, although the presence of immunogenic peptides arising from the junction between tCD34 and TK39 and from the TK39 protein itself cannot be excluded. Also preliminary results have shown that the ectopic expression of human tCD34 on murine hematopoietic stem cells does not alter multilineage hematopoiesis in vivo (B Fehse, personal communication), pointing to a possible use in this setting for therapeutic purposes without alteration of T-cell function.
The use of the GCV-hypersensitive TK39 mutant in conjunction with tCD34 offers some advantages over previously used suicide systems. In contrast to the use of the neomycin phosphotransferase gene that allows the selection of transduced cells after long in vitro culture selection, 24 ,25 the tCD34 surface marker provides means for immunomagnetic selection of GMCs, thereby reducing the time of ex vivo culture with preservation of the innate properties of transduced cells. 25 Furthermore, the use of a hypersensitive mutant of TK, TK39, may improve significantly the clinical outcome of T-cell-based therapies, since recent clinical experiences have raised concerns about the myelosuppressive side effects of GCV at the doses required to induce apoptosis in wild-type TK-transduced cells 26, 27 The TK39 mutant allows elimination of engineered cells in vitro at GCV concentrations below 1 mM. At this low dose it is unlikely that significant marrow suppression occurs. Up to 99% of the cells transduced with the MtCD34TK39mw vector were eliminated after 4 days treatment with 1 mM GCV, a log dose lower than that required to eliminate cells expressing wild-type TK. 28 Nevertheless, there was a clear time-dependent effect of cell killing by GCV, probably a reflection of cell cycle dependency of GCV action. 29 As an alternative to MtCD34TK39mw, a second vector was constructed (MNV 0 VDEDw) in which the DED of FADD was fused to a truncated version of the cell surface marker LNGFR. The activation of DED by dimerization was accomplished through two CID-binding proteins, as previously described by Thomis et al 14 The DED of FADD was chosen as primary signal inducing cell death since a systematic screening of several effector molecules triggering cell death showed that the DED of FADD was effective in inducing apoptosis with minimal basal toxicity in the absence of dimerizer. 30 The DED-containing vector allowed an effective elimination of engineered primary human T lymphocytes within 24 h. Up to 90% of the DED-expressing cells were eradicated after addition of the dimerizer inductor AP20187. Similar observations have been reported by Thomis et al, 14 using a CIDdependent Fas construct to induce apoptosis of transduced T cells.
In order to compare the performance of both constructs, primary T cells and T cell lines were transduced using previous established protocols. Prior to transduction, purified CD3+ T lymphocytes were stimulated with antibodies against CD3 and CD28 in the presence of IL-2. This combination allows for the preservation of most of the T-cell functions, an essential prerequisite for the application of GMCs in DLI strategies. 25 Transduced cells were purified to more than 90% purity using conventional immunomagnetic devices. Most important, no activation of cell death was detected in cells transduced with the MNV 0 VDEDw construct, indicating that antibody crosslinking is not sufficient to trigger receptor dimerization. A semiquantitative PCR analysis for proviral integration showed similar proviral copy numbers in both populations. Transduced cells were treated in parallel with either GCV or AP20187. A single exposure of MNV 0 VDEDw-transduced cells to AP20187 resulted in a significant elimination of cells (up to 67%) within the first 24 h. Further exposure to the drug resulted in a decrease in the number of viable cells (up to 85%). However, a plateau of surviving cells was observed between 72 and 96 h of treatment with no further increase in the number of dead cells. Cells surviving the initial treatment were apparently resistant to further drug applications and continued to grow even in the presence of AP20187. A FACS analysis of this population revealed that 10% of them retained expression of tLNGFR. Our observations are in agreement with previous published data in which a partial resistance of a small fraction of T cells to apoptotic signals was reported. [31] [32] [33] [34] In contrast, only a small fraction of MtCD34TK39mw-transduced cells was eliminated after 24 h incubation with GCV. Significant cell death was observed after 3-4 days treatment. However, the total number of surviving cells at day 4 of treatment was lower in the GCV-treated population than in the AP20187-treated cells. This observation suggests that DED-containing vectors are more efficient than TK39-containing vectors in killing transduced cells within a short time period, but an almost complete elimination of transduced cells is achieved only in GCV-treated cells after a few days treatment. Our results indicate that the most effective strategy to eliminate alloreactive T cells would be the combination of both systems within one vector. Indeed, T cells expressing both the TK39 and DED fusion genes were completely eliminated within 72 h treatment with a combination of GCV and AP20187 (unpublished results). Also the use of both sucide genes would eliminate both proliferating and resting T -cells, thus avoiding the development of chronic GVHD, which is thought to be caused by slow replicating alloreactive TK-expressing lymphocytes which are not eliminated after GCV treatment. 6 Kinetics of cell death triggered by suicide genes K Junker et al
One major drawback in the use of TK39 is its high drug sensitivity for both GCV and ACV, 15 thus precluding the use of ACV as an antiviral drug in patients treated with TK39-transduced cells. Cidofovir, an antiviral drug with the same application range as GCV and ACV, could be used instead of ACV in cases of acute viral infections. As a nucleoside monophosphate, Cidofovir is not phosphorylated by the viral thymidine kinase and affects transduced and nontransduced cells equally. Treatment of viral infections in adults with Cidofovir results in serum levels between 40 and 70 mM, significantly below the concentration required for the elimination of transduced and untransduced cells. Therefore Cidofovir represents a real alternative to ACV for the treatment of viral infections in patients treated with TK39-modified T cells.
Materials and methods
Retroviral constructs
MtCD34TK39mw was derived from pSFa11tCD34. 18, 35 In a first step, the 3 0 LTR of pSFa11tCD34 was replaced by the LTR of the MPSV 21 . Subsequently, a post-transcriptional regulatory element derived from the Woodchuck hepatitis virus (WPRE) 22 was inserted at the 3 0 -end of tCD34. The HSV-TK39 sequence was derived by PCR from pET23dHSV-TK39. 28 and fused in frame to the 3 0 -end of tCD34 upstream of WPRE. Furthermore, the cryptic splice donor site within the TK gene 13 was eliminated by site-directed mutagenesis. In MNV 0 VDEDw an intracytoplasmic truncated version of the human low-affinity receptor for nerve growth factor (tLNGFR) 19 was fused in frame to two divergent copies of a modified FK506 binding protein called FKBP 36v 20 lacking the myristoylation signal and the HA-tag. Subsequently, a DNA fragment coding for the DED of FADD was amplified by PCR from FADD-ERt plasmid (kindly provided by EW Humke and VM Dixit, Department of Molecular Oncology, Genetech, South San Francisco, USA) and fused in frame to the 3 0 -end of tLNGFR/F36V 0 F36V to generate tLNGFR/F36V 0 F36V/ DED. This construct was used to replace the tCD34/ TK39wm insert in MtCD34TK39mw. The correct assembly of the constructs was confirmed by DNA sequencing.
Cells and retroviral supernatants
Human primary T lymphocytes were isolated from buffy-coats obtained from healthy donors. T lymphocytes were enriched by MACS with CD3 monoclonal antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were then cryopreserved in 10% dimethyl sulfoxide (DMSO, Sigma, St Louis, MO, USA) or kept in culture as indicated below. The purity of CD3+ T lymphocytes exceeded 95%. HUT 78, a CD3+/CD4+ T-cell lymphoma cell line (ATCC TIB-161), was cultured in RPMI 1640 (Gibco BRL, Karlsruhe, Germany) containing 10% FCS, 4 mM L-glutamine and 1% penicillin/ streptomycin. Retroviral vector-containing supernatants were obtained either after transient transfection of Phoenix gp cells 36 with a GALV envelope 23 (titer 1 Â 10 6 TU/ml) or from stable PG13 producer cells (6 Â 10 5 TU/ml) 37 .
Retroviral transduction and immunomagnetic selection of transduced cells
CD3-enriched human T lymphocytes were stimulated for 3 days with a combination of OKT-3 (20 ng/ml; JanssenCilag GmbH, Neuss, Germany), human recombinant interleukin-2 (IL-2; 1000 U/ml; Roche, Mannheim, Germany) and the anti-CD28 monoclonal antibody CD28.2 (1 mg/ml; BD Pharmingen, Heidelberg, Germany), in RPMI 1640 (Gibco BRL, Karlsruhe, Germany), 10% FCS, 1% penicillin/streptomycin and 4 mM L-glutamine (CMmedia). Thereafter, 1x10 6 cells were transduced for 4 h by a spinoculation step (90 min centrifugation at 1257 g at 321C) on Retronectin (CH296, 50 mg/ml, BioWhittaker, Heidelberg, Germany)-coated nontissue culture plates (BD-Falcon, Heidelberg, Germany). The transduction procedure was repeated on 2-3 consecutive days. After 5 days, the last transduction cells were enriched for CD34 or LNGFR expression by MACS using CD34/QBEND-10 microbeads or NGFR Me20.4 antibodies (Sigma, Taufkirchen, Germany) in combination with goat anti-mouse IgG1 microbeads (Milteniy, Bergisch-Gladbach, Germany) according to the manufacturer's instruction. For FACS analysis transduced cells were labeled either with phycoerythrin (PE)-coupled anti-CD34 (HPCA-2) or PE-LNGFR (C40-1457) antibodies. HUT 78 cells were transduced similarly using protamínsulfate (4 mg/ml) instead of CH296-coated plates followed by immunomagnetic separation as indicated above.
Cell death assays
A volume of 1 Â 10 5 HUT 78 or 5 Â 10 5 primary T cells were incubated on 24-well or 48-well tissue-culture plates in 1 ml RPMI supplemented with L-glutamine (4 mM), 1% PenStrp, 10% FCS (and 1000 U/ml IL-2 for primary T cells) with increasing concentrations of either GCV (Cymeven, Hoffmann-La Roche, Grenzach, Suisse) or the chemical inducer of dimerization (CID) AP20187 (Ariad, Cambridge, MA, USA; www.ariad.com/regulationkits) for MtCD34TK39mw-or MNV 0 VDEDw-transduced cells, respectively. After treatment, primary T cells were labeled either with FITC-CD34 or FITC-NGFR for 20 min at 41C followed by staining with propidium iodide (PI), and analyzed on a Becton Dickinson FACSCalibur. The amount of cell death was estimated from the surviving CD34-or LNGFR-expressing cells within the living cell population. Cell death in transduced HUT 78 cells was assessed following drug incubation by MTS assays (Celltiter 96
s Aqueous one solution cell proliferation assay, Promega, Mannheim, Germany) 38 according to the manufacturer's instructions. The effects of the drugs on transduced cells were expressed as a ratio of (OD 490 +drug/OD 490 Àdrug) Â 100.
Analysis of alloreactivity against leukemic cells
Cytotoxicity of transduced and nontransduced T cells was tested against allogeneic bone marrow samples containing more than 90% leukemic blasts. Effector and target cells were cocultured for 24-48 h at ratios of 1:4, 1:1, 5:1 and 10:1, respectively. The degree of cytotoxicity was assessed by flow cytometric analysis. For this purpose, cells were labeled with FITC-and PE-conjugated monoclonal antibodies recognizing target cell epitopes (CD10, CD19, CD33, CD34, Coulter Immunotech, Marseille, France). PI was used to identify dead Kinetics of cell death triggered by suicide genes K Junker et al cells. An internal standard was added for absolute counting of cell numbers. Samples were measured on a four-color Epics XL-MCL with System II software (Beckmann Coulter, Krefeld, Germany). Cytotoxicity was defined as the decrease in the number of viable target cells and is expressed as percent of initial viable target cells minus the spontaneous cell death in controls. 39 
